Postdoctoral position in microfluidic RNAseq-based screening for optimal T-cell expansion protocols — EPFL
- Location
- Lausanne
- Contract
- full-time
- Posted
- Yesterday
Role overview
Mission
The Laboratory of Biomedical Microfluidics (LBMM; www.epfl.ch/labs/lbmm ) at the Swiss Federal Institute of Technology in Lausanne (EPFL), is looking for postdocs with a primary training in cell biology and next generation sequencing.
Experience in droplet-microfluidics, including use of commercial devices such as the 10X Genomics platform is beneficial, but not absolutely crucial.
- Mission
- The Laboratory of Biomedical Microfluidics (LBMM; www.epfl.ch/labs/lbmm ) at the Swiss Federal Institute of Technology in Lausanne (EPFL), is looking for postdocs with a primary training in cell biology and next generation sequencing.
- Main duties and responsibilities include
- Optimization of microfluidic and biochemical workflows
- Hands-on experience in cell biology and NGS
- Good knowledge in T-cell expansion and therapy Motivated in driving tech development
Main responsibilities
- Main duties and responsibilities include
- Optimization of microfluidic and biochemical workflows
- Development of miniaturized T-cell expansion assays, including feeder cells Preparation of NGS libraries
- Data analysis with help from a bioinformatics facility
Key requirements
- Hands-on experience in cell biology and NGS
- Good knowledge in T-cell expansion and therapy Motivated in driving tech development
- Prior experience in microfluidics is advantageous but not absolutely required Good communication skills We offer A multidisciplinary environment
- Exposure to the latest cutting-edge experimental procedures (e.g. custom microfluidic platforms and sequencing approaches)
- Preparation for a future career in academia, industry or startup companies Informations
Application process
- Having a comprehensive microfluidic toolbox at hand (and expanding it continuously), we are now inviting applications for highly multiplexed RNAseq-based screening for optimal T-cell expansion protocols.
- In close collaboration with the lab of George Coukos ( https://agora-cancer.ch/laboratory/coukos-lab/ ), we will derive protocols enabling rapid expansion of cancer-specific, autologous TILs for clinical application.
- The project will be based on repurposing existing microfluidic platforms (e.g.
- Mathur et al., Nature Communications, Utharala et al., Nature Protocols).
- The LBMM has a very translational focus, running a tech development lab on the EPFL campus and a translational lab in the AGORA cancer research center (with direct access to patient material).
- Furthermore, a strong network of clinical partners in Europe and the US has been established.
- The successful candidate will closely interact with experts in microfluidics and bioinformatics, while spearheading the above project.
- Only applications submitted through the online platform are considered. You are asked to supply: A brief cover letter (pdf, up to 2 pages). And in one PDF: A CV with a publication list. A research statement (pdf, up to 3 pages).
Contacts
- For any further information, please contact: Prof.
- Christoph Merten, [email protected] Contract Start Date : 01/01/2027
- Activity Rate : 100.00 Contract Type: CDD Duration: 1 year, renewable Reference: 2442
Additional details
- details for 3 referees.
- Development of miniaturized T-cell expansion assays, including feeder cells Preparation of NGS libraries
- Good knowledge in T-cell expansion and therapy Motivated in driving tech development
- Prior experience in microfluidics is advantageous but not absolutely required Good communication skills A multidisciplinary environment
- Preparation for a future career in academia, industry or startup companies
- Only applications submitted through the online platform are considered. You are asked to supply: A brief cover letter (pdf, up to 2 pages). A CV with a publication list. A research statement (pdf, up to 3 pages).
- Contact details for 3 referees.
- Christoph Merten, [email protected] Contract Start Date : 01/01/2027
- Activity Rate : 100.00 Duration: 1 year, renewable
Notes and original content
- Development of miniaturized T-cell expansion assays, including feeder cells
- Preparation of NGS libraries
- Your profile
- Good knowledge in T-cell expansion and therapy
- Motivated in driving tech development
- Prior experience in microfluidics is advantageous but not absolutely required
- Good communication skills
- A multidisciplinary environment
- Informations
- Only applications submitted through the online platform are considered.
Questions about this listing
What salary does EPFL offer for this role?
EPFL lists CHF 60'500 - 91'500 gross per year for this position in Lausanne. This is the salary published in the original listing (or, when the employer omits a figure, a realistic estimate for the role and sector) — the calculator on this site converts it to your actual net take-home once cross-border tax and social contributions are applied.
Is this a full-time role, and what type of contract does EPFL offer?
This listing is a full-time position. The contract type shown here comes directly from the employer's original posting; always confirm exact hours, notice period and probation length with EPFL during the application process, since these details can vary by role even within the same contract category.
Do I need a cross-border work permit for a role in Vaud?
EU/EFTA residents living in the border zone of the country adjoining Canton Vaud can apply for a G permit; the Swiss employer files it with that canton's migration office after the contract is signed. Border-zone rules and processing times vary by neighbouring country and canton, so confirm the specifics with Vaud's cantonal migration office or with HR during the application.
How do I apply for this position at EPFL?
Use the "Apply now" button on this page — it links directly to EPFL's original listing at careers.epfl.ch, so your application goes straight to the employer's own applicant-tracking system. Frontaliere Ticino does not collect or forward applications itself.
